Pfizer Inc (NYSE:PFE) had a stellar first quarter in terms of profit, which grew by 61% to $7.8 billion on the sales of its COVID-19 vaccine, which reached $13 billion. The company, however, adjusted its earnings per share outlook for this year by 10 cents.

Pfizer’s earnings report

As reported by ABC News, Pfizer expects readjusted earnings of $6.25 to $6.45 per share, down from $6.35 to $6.55 per share. Meanwhile, analysts estimate earnings of $7.14 per share.

The lower earnings guidance is due to rising research and development costs and the strengthening of the U.S. dollar. Still, the company is aiming at $98 billion to $102 billion in total sales this year.

But the pharma giant also had a solid first quarter in terms of revenue, which hit $25 billion or a 77% increase from the same period last year. Refinitiv estimates had pointed to $23.8 billion.

The company said the welcoming quarter results were driven by the sales of booster shots and the development of the vaccine for children.

Vaccine sales outlook

For the year 2022, financial results are bound to rely on Covid vaccine sales. Pfizer has anticipated sales of $32 billion in vaccine sales and $22 billion for Paxlovid, the company’s antiviral treatment.

Chairman and CEO Albert Bourla told analysts Tuesday, “We are seeing strong signs for increasing demand for Paxlovid.”

Pfizer’s Covid shot is at the top of applications in both the U.S. and the European Union, while the company seeks authorization for the three-dose vaccine for under-five-year-olds. Mikael Dolsten, the firm’s chief scientific officer, said Pfizer would submit third-dose data by the end of May or early June.

As reported by The Guardian, a pharma campaigner from Global Justice Now has accused Pfizer of profiteering on the huge sales of its Covid vaccine and treatments.

Tim Bierley said, “Throughout the pandemic, Pfizer has refused to share its technology and know-how. Instead, it has maintained monopoly control over its vaccine and treatment, keeping a chokehold on global supply.”

Share: Feed news

VALUEWALK LLC is not a registered or licensed investment advisor in any jurisdiction. Nothing on this website or related properties should be considered personalized investments advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. VALUEWALK LLC, its managers, its employees, affiliates and assigns (collectively “The Company”) do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. The Company disclaims any liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses.

Recommended content


Recommended content

Editors’ Picks

Australian Dollar extends gains despite  mixed PMI

Australian Dollar extends gains despite mixed PMI

The Australian Dollar (AUD) continues to strengthen against the US Dollar (USD) following the release of mixed Judo Bank Purchasing Managers' Index (PMI) data from Australia on Friday. The AUD also benefits from a hawkish outlook by the Reserve Bank of Australia (RBA) regarding future interest rate decisions. 

AUD/USD News
Japanese Yen fails to build on stronger CPI-led intraday uptick against USD

Japanese Yen fails to build on stronger CPI-led intraday uptick against USD

The Japanese Yen (JPY) attracted some follow-through buying for the second successive day following the release of slightly higher-than-expected consumer inflation figures from Japan. This comes on top of Thursday's hawkish remarks from BoJ Governor Kazuo Ueda, which keeps expectations for a December interest rate hike in play.

USD/JPY News
Gold price advances to near two-week top on geopolitical risks

Gold price advances to near two-week top on geopolitical risks

Gold price touched nearly a two-week high during the Asian session as the worsening Russia-Ukraine conflict benefited traditional safe-haven assets. The weekly uptrend seems unaffected by bets for less aggressive Fed policy easing, sustained USD buying and the prevalent risk-on environment

Gold News
Ethereum Price Forecast: ETH open interest surge to all-time high after recent price rally

Ethereum Price Forecast: ETH open interest surge to all-time high after recent price rally

Ethereum (ETH) is trading near $3,350, experiencing an 10% increase on Thursday. This price surge is attributed to strong bullish sentiment among derivatives traders, driving its open interest above $20 billion for the first time. 

Read more
A new horizon: The economic outlook in a new leadership and policy era

A new horizon: The economic outlook in a new leadership and policy era

The economic aftershocks of the COVID pandemic, which have dominated the economic landscape over the past few years, are steadily dissipating. These pandemic-induced economic effects are set to be largely supplanted by economic policy changes that are on the horizon in the United States.

Read more
Best Forex Brokers with Low Spreads

Best Forex Brokers with Low Spreads

VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.

Read More

Forex MAJORS

Cryptocurrencies

Signatures